View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
February 6, 2020updated 12 Jul 2022 11:57am

US trial evaluates osteoporosis drug to prevent breast cancer

Researchers at Washington University School of Medicine in St Louis, US, are evaluating osteoporosis drug denosumab in a Phase II clinical trial to prevent breast cancer in women.

Researchers at Washington University School of Medicine in St Louis, US, are evaluating osteoporosis drug denosumab in a Phase II clinical trial to prevent breast cancer in women.

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

The National Cancer Institute (NCI) at the National Institutes of Health (NIH) has granted $3m to support the five-year trial, which will investigate the drug’s ability to reduce breast density.

Women with dense breasts are at a four to six times greater risk of developing breast cancer compared to those with a lower breast density.

In 2010, denosumab received US Food and Drug Administration (FDA) approval to treat osteoporosis. The new trial will assess the drug’s potential to lower breast density in premenopausal women with the aim of preventing breast cancer in the future.

Washington University School of Medicine in St Louis division of public health sciences surgery associate professor Adetunji Toriola said: “About 25% of breast cancers are diagnosed in premenopausal women, but we have only one preventive therapy that has been approved for this group, tamoxifen, a chemotherapy drug that has undesirable side effects, including early menopause.

“While severe side effects are rare, tamoxifen increases a woman’s risk of developing endometrial cancer, blood clots and stroke.”

Researchers aim to develop preventive therapies that can offer an alternative to tamoxifen.

For the Phase II trial, the team will enrol 210 volunteers receiving annual screening mammography at Siteman Cancer Center. Participants must be aged 40 and above, cancer-free, premenopausal, and have dense breasts.

Denosumab is designed to inhibit a molecular signalling pathway called RANK, which is linked to bone remodelling regulation, the development of fibrous mammary gland structures, and breast cancer in experimental models.

Toriola added: “The safety and effectiveness of this drug is well established in its use as an FDA-approved therapy to prevent osteoporosis and bone fractures in older women.

“So we hope that denosumab will provide an additional prevention option for women with dense breasts who are at high risk of developing breast cancer.”

The drug comes with side effects such as low calcium levels, muscle pain and degeneration of the jaw bone, which is said to be resolved after discontinuing the drug.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena